{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:41:08Z","timestamp":1792424468150,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01952-0","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:44:02Z","timestamp":1792377842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Restoration of cyclin A2 by glabridin reverses pathological cell cycle arrest and drives cardiac repair in HFpEF"],"prefix":"10.1038","author":[{"given":"Meng-yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-ru","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha-sha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-quan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-jun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-qun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"1952_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/eurheartj\/ehu067","volume":"35","author":"M Komajda","year":"2014","unstructured":"Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014;35:1022\u201332.","journal-title":"Eur Heart J"},{"key":"1952_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","volume":"4","author":"M Haass","year":"2011","unstructured":"Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324\u201331.","journal-title":"Circ Heart Fail"},{"key":"1952_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11897-014-0223-7","volume":"11","author":"A Dhingra","year":"2014","unstructured":"Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014;11:354\u201365.","journal-title":"Curr Heart Fail Rep"},{"key":"1952_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.pcad.2020.04.011","volume":"63","author":"MG Del Buono","year":"2020","unstructured":"Del Buono MG, Iannaccone G, Scacciavillani R, Carbone S, Camilli M, Niccoli G, et al. Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence. Prog Cardiovasc Dis. 2020;63:570\u201384.","journal-title":"Prog Cardiovasc Dis"},{"key":"1952_CR5","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s12265-025-10699-8","volume":"18","author":"XX Cui","year":"2025","unstructured":"Cui XX, Hu YX, Xu YW, Yang LX, Chatterjee E, Li GP, et al. Systemic interactions in HFpEF: a multiorgan perspective on pathways and therapeutic targets. J Cardiovasc Transl Res. 2025;18:1876\u201392.","journal-title":"J Cardiovasc Transl Res"},{"key":"1952_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18:400\u201323.","journal-title":"Nat Rev Cardiol"},{"key":"1952_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568:351\u20136.","journal-title":"Nature"},{"key":"1952_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156460","volume":"176","author":"M Ye","year":"2026","unstructured":"Ye M, Feng SH, Xu ZX, He WF, Liu C, Zhu WG. Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications. Metabolism. 2026;176:156460.","journal-title":"Metabolism"},{"key":"1952_CR9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.tibs.2019.06.011","volume":"44","author":"M Ogrodnik","year":"2019","unstructured":"Ogrodnik M, Salmonowicz H, Jurk D, Passos JF. Expansion and cell-cycle arrest: common denominators of cellular senescence. Trends Biochem Sci. 2019;44:996\u20131008.","journal-title":"Trends Biochem Sci"},{"key":"1952_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106488","volume":"141","author":"H Sutanto","year":"2025","unstructured":"Sutanto H, Fetarayani D, Narendra MR, Nasution SA. The role of the senescence-associated secretory phenotype in cardiovascular disease among the elderly. Eur J Intern Med. 2025;141:106488.","journal-title":"Eur J Intern Med"},{"key":"1952_CR11","first-page":"27","volume":"9","author":"XY Feng","year":"2025","unstructured":"Feng XY, Wei ZY, Hu YJ, Chen T, Yu BQ. Stem cell-based strategies for vascular aging: from mechanistic insights to clinical translation. Vessel Plus. 2025;9:27.","journal-title":"Vessel Plus"},{"key":"1952_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-3-642-19065-0_17","volume":"53","author":"DJ Wolgemuth","year":"2011","unstructured":"Wolgemuth DJ. Function of the A-type cyclins during gametogenesis and early embryogenesis. Results Probl Cell Differ. 2011;53:391\u2013413.","journal-title":"Results Probl Cell Differ"},{"key":"1952_CR13","doi-asserted-by":"publisher","first-page":"35858","DOI":"10.1074\/jbc.M404975200","volume":"279","author":"HW Chaudhry","year":"2004","unstructured":"Chaudhry HW, Dashoush NH, Tang HY, Zhang L, Wang XY, Wu EX, et al. Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem. 2004;279:35858\u201366.","journal-title":"J Biol Chem"},{"key":"1952_CR14","doi-asserted-by":"publisher","first-page":"I206","DOI":"10.1161\/CIRCULATIONAHA.105.000455","volume":"114","author":"YJ Woo","year":"2006","unstructured":"Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Hsu VM, et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation. 2006;114:I206\u201313.","journal-title":"Circulation"},{"key":"1952_CR15","doi-asserted-by":"publisher","first-page":"224ra27","DOI":"10.1126\/scitranslmed.3007668","volume":"6","author":"SD Shapiro","year":"2014","unstructured":"Shapiro SD, Ranjan AK, Kawase Y, Cheng RK, Kara RJ, Bhattacharya R, et al. Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes. Sci Transl Med. 2014;6:224ra27.","journal-title":"Sci Transl Med"},{"key":"1952_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41536-025-00438-7","volume":"10","author":"E Bouhamida","year":"2025","unstructured":"Bouhamida E, Vadakke-Madathil S, Mathiyalagan P, Ranjan AK, Khan A, Sherman CD, et al. Cyclin A2 induces cytokinesis in human adult cardiomyocytes and drives reprogramming in mice. NPJ Regen Med. 2025;10:47.","journal-title":"NPJ Regen Med"},{"key":"1952_CR17","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/CIRCRESAHA.107.153544","volume":"100","author":"RK Cheng","year":"2007","unstructured":"Cheng RK, Asai T, Tang HY, Dashoush NH, Kara RJ, Costa KD, et al. Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res. 2007;100:1741\u20138.","journal-title":"Circ Res"},{"key":"1952_CR18","doi-asserted-by":"crossref","unstructured":"Sharifi-Rad J, Rodrigues CF, Sharopov F, Docea AO, Can Karaca A, Sharifi-Rad M, et al. Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds. Int J Environ Res Public Health. 2020;17:2326.","DOI":"10.3390\/ijerph17072326"},{"key":"1952_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.fitote.2013.07.003","volume":"90","author":"C Simmler","year":"2013","unstructured":"Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160\u201384.","journal-title":"Fitoterapia"},{"key":"1952_CR20","doi-asserted-by":"crossref","unstructured":"Wang MY, Zhang F, Zhou J, Gong K, Chen SS, Zhu XR, et al. Glabridin ameliorates alcohol-caused liver damage by reducing oxidative stress and inflammation via the p38 MAPK\/Nrf2\/NF-kappaB pathway. Nutrients. 2023;15:2157.","DOI":"10.3390\/nu15092157"},{"key":"1952_CR21","doi-asserted-by":"crossref","unstructured":"Tipbunjong C, Khimmaktong W, Hengpratom T, Thitiphatphuvanon T, Pholpramool C, Surinlert P. Glabridin alleviates oxidative stress-induced osteoporosis by targeting the Akt\/NF-kB and Akt\/GSK-3beta pathways. Int J Mol Sci. 2025;26:2949.","DOI":"10.3390\/ijms26072949"},{"key":"1952_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109433","volume":"113","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang HB, Gu JH, Xu WQ, Yuan NP, Sun JL, et al. Glabridin inhibits liver fibrosis and hepatic stellate cells activation through suppression of inflammation and oxidative stress by activating PPARgamma in carbon tetrachloride-treated mice. Int Immunopharmacol. 2022;113:109433.","journal-title":"Int Immunopharmacol"},{"key":"1952_CR23","first-page":"107","volume":"17","author":"GX Wang","year":"2019","unstructured":"Wang GX, Sun GC, Wang Y, Yu P, Wang X, Zhou BR, et al. Glabridin attenuates endothelial dysfunction and permeability, possibly via the MLCK\/p-MLC signaling pathway. Exp Ther Med. 2019;17:107\u201314.","journal-title":"Exp Ther Med"},{"key":"1952_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.intimp.2015.10.020","volume":"29","author":"MR Kang","year":"2015","unstructured":"Kang MR, Park KH, Oh SJ, Yun J, Lee CW, Lee MY, et al. Cardiovascular protective effect of glabridin: Implications in LDL oxidation and inflammation. Int Immunopharmacol. 2015;29:914\u20138.","journal-title":"Int Immunopharmacol"},{"key":"1952_CR25","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1002\/ptr.8517","volume":"39","author":"XX Yang","year":"2025","unstructured":"Yang XX, Lai KY, Zhang JY, Chen ZY, Ding WW, Jiang Y, et al. Glabridin alleviates metabolic disorders in diet-induced diabetic mice. Phytother Res. 2025;39:5551\u201366.","journal-title":"Phytother Res"},{"key":"1952_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10020-022-00481-w","volume":"28","author":"HT Tan","year":"2022","unstructured":"Tan HT, Chen JX, Li YC, Li YS, Zhong YC, Li GZ, et al. Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF\/Akt\/ERK pathways. Mol Med. 2022;28:58.","journal-title":"Mol Med"},{"key":"1952_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13701","volume":"57","author":"AQ Khan","year":"2024","unstructured":"Khan AQ, Agha MV, Ahmad F, Anver R, Sheikhan KSAM, Mateo J, et al. Metabolomics analyses reveal the crucial role of ERK in regulating metabolic pathways associated with the proliferation of human cutaneous T-cell lymphoma cells treated with Glabridin. Cell Prolif. 2024;57:e13701.","journal-title":"Cell Prolif"},{"key":"1952_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","volume":"128","author":"Y Deng","year":"2021","unstructured":"Deng Y, Xie MD, Li Q, Xu XW, Ou W, Zhang YB, et al. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF. Circ Res. 2021;128:232\u201345.","journal-title":"Circ Res"},{"key":"1952_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61067-8","volume":"16","author":"MY Wang","year":"2025","unstructured":"Wang MY, Wen X, Feng ZA, Choubey M, Chen SS, Pan RR, et al. ACSS2 protects against alcohol-induced hepatocyte ferroptosis through regulation of hepcidin expression. Nat Commun. 2025;16:5491.","journal-title":"Nat Commun"},{"key":"1952_CR30","first-page":"19","volume":"9","author":"P Siriwattanawong","year":"2025","unstructured":"Siriwattanawong P, Justin R, Gamachchige PR, Zhou DC, Chen T. Endothelial dysfunction as a driver of microvascular injury in diabetic cardiomyopathy. Vessel Plus. 2025;9:19.","journal-title":"Vessel Plus"},{"key":"1952_CR31","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124:1598\u2013617.","journal-title":"Circ Res"},{"key":"1952_CR32","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3892\/etm.2014.1935","volume":"8","author":"HL Deng","year":"2014","unstructured":"Deng HL, Cheng Y, Guo ZK, Zhang FX, Lu X, Feng LL, et al. Overexpression of CyclinA2 ameliorates hypoxia-impaired proliferation of cardiomyocytes. Exp Ther Med. 2014;8:1513\u20137.","journal-title":"Exp Ther Med"},{"key":"1952_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2018.02.014","volume":"173","author":"TMA Mohamed","year":"2018","unstructured":"Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173:104\u201316.e12.","journal-title":"Cell"},{"key":"1952_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1164680","volume":"324","author":"O Bergmann","year":"2009","unstructured":"Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe- HeiderF, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98\u2013102.","journal-title":"Science"},{"key":"1952_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(95)90338-0","volume":"81","author":"RW King","year":"1995","unstructured":"King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P, Kirschner MW. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell. 1995;81:279\u201388.","journal-title":"Cell"},{"key":"1952_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1083\/jcb.153.1.137","volume":"153","author":"S Geley","year":"2001","unstructured":"Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, Hunt T. Anaphase-promoting complex\/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol. 2001;153:137\u201348.","journal-title":"J Cell Biol"},{"key":"1952_CR37","first-page":"2145","volume":"127","author":"A Loukil","year":"2014","unstructured":"Loukil A, Zonca M, Rebouissou C, Baldin V, Coux O, Biard-Piechaczyk M, et al. High-resolution live-cell imaging reveals novel cyclin A2 degradation foci involving autophagy. J Cell Sci. 2014;127:2145\u201350.","journal-title":"J Cell Sci"},{"key":"1952_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41556-020-0554-4","volume":"22","author":"A Nowosad","year":"2020","unstructured":"Nowosad A, Jeannot P, Callot C, Creff J, Perchey RT, Joffre C, et al. p27 controls Ragulator and mTOR activity in amino acid-deprived cells to regulate the autophagy-lysosomal pathway and coordinate cell cycle and cell growth. Nat Cell Biol. 2020;22:1076\u201390.","journal-title":"Nat Cell Biol"},{"key":"1952_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc3960","volume":"15","author":"NE Sharpless","year":"2015","unstructured":"Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397\u2013408.","journal-title":"Nat Rev Cancer"},{"key":"1952_CR40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1952_CR41","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"1952_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.05.004","volume":"10","author":"A Hakeem","year":"2025","unstructured":"Hakeem A, van Berlo J, Revelo XS. The cardiohepatic axis in metabolic disease. Liver to heart. JACC Basic Transl Sci. 2025;10:101309.","journal-title":"JACC Basic Transl Sci"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01952-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:03:11Z","timestamp":1792422191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01952-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":42,"alternative-id":["1952"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01952-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}